The most well known BCR-ABL tyrosine kinase inhibitor (TKI), imatinib mesylate, induces a complete hematologic and cytogenetic response in the majority of chronic myeloid leukemia (CML) patients in chronic phase [27,28,29]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.